Screening for Significant Fibrosis in Patients with Obesity
GI InsightsScreening for Significant Fibrosis in Patients with Obesity
Fernando Bril, MD
Obesity and Liver Disease: Getting to the Core of Treatment
GI InsightsObesity and Liver Disease: Getting to the Core of Treatment
Fernando Bril, MD
Is Lifestyle Intervention Enough for Obesity and MASLD?
GI InsightsIs Lifestyle Intervention Enough for Obesity and MASLD?
Fernando Bril, MD
The Emerging Role of Triple Agonists in Obesity Management
Clinician's RoundtableThe Emerging Role of Triple Agonists in Obesity Management
Javier Morales, MD, FACP, FACE
Peter Buch, MD, FACG, AGAF, FACP
David Tendler, MD
Personalizing Nutrition and Exercise Alongside GLP-1 Receptor Agonist Therapy
Diabetes DiscoursePersonalizing Nutrition and Exercise Alongside GLP-1 Receptor Agonist Therapy
Laura Chiavaroli, PhD
- advertisement
- 3 questions
- advertisement
Albuminuria: An Overlooked Red Flag in Cardiovascular Risk
Conversations in CV Risk AssessmentAlbuminuria: An Overlooked Red Flag in Cardiovascular Risk
Matthew Sorrentino, MD
Ashish Verma, MBBS
Hidden High Risk: When BP Control Isn’t Enough in Hypertension
Conversations in CV Risk AssessmentHidden High Risk: When BP Control Isn’t Enough in Hypertension
Gates B. Colbert, MD
Michael E. Hall, MD
Clyde W. Yancy, MD
Rethinking Diabetes Care: Key Data from Incorporating Lifestyle Modifications
Medical Industry FeatureRethinking Diabetes Care: Key Data from Incorporating Lifestyle Modifications
Charles Turck, PharmD, BCPS, BCCCP
Jamy Ard, MD
Michelle I. Cardel, PhD, MS, RD
- 11/04/2026
- 11/04/2026
- 11/04/2026
- 11/03/2026
- 11/03/2026
- 10/30/2026